Neuronetics Inc - Asset Resilience Ratio
Neuronetics Inc (STIM) has an Asset Resilience Ratio of 0.20% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Neuronetics Inc (STIM) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Neuronetics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see STIM total assets.
Liquid Assets Composition Over Time
This chart breaks down Neuronetics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Neuronetics Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $257.00K | 0.2% |
| Total Liquid Assets | $257.00K | 0.20% |
Asset Resilience Insights
- Limited Liquidity: Neuronetics Inc maintains only 0.20% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Neuronetics Inc Industry Peers by Asset Resilience Ratio
Compare Neuronetics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medtronic plc
SA:MDTC34 |
Medical Devices | 7.82% |
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Biosynex
PA:ALBIO |
Medical Devices | 3.35% |
Annual Asset Resilience Ratio for Neuronetics Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Neuronetics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.16% | $225.00K | $141.55 Million | +0.01pp |
| 2024-12-31 | 0.15% | $206.00K | $140.90 Million | -0.64pp |
| 2023-12-31 | 0.78% | $905.00K | $115.83 Million | -0.53pp |
| 2022-12-31 | 1.32% | $1.54 Million | $116.88 Million | -0.24pp |
| 2021-12-31 | 1.56% | $2.20 Million | $141.22 Million | -0.84pp |
| 2020-12-31 | 2.40% | $1.89 Million | $78.66 Million | +1.52pp |
| 2019-12-31 | 0.88% | $880.00K | $100.17 Million | -- |
About Neuronetics Inc
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a p… Read more